Portrait of LoBiondo, Frank A.

LoBiondo, Frank A.

U.S. Representative NJ-2 Republican Party

Congressional stock trade history disclosed under the STOCK Act, as filed.

Disclosed trades
75
Buys / sells
21% / 76%
Last trade
Dec 14, 2018
Last filing
Dec 20, 2018

Latest disclosed trades

Latest 10 of 75
Ticker Type Traded
BLK Buy Dec 14, 2018
GIS Sell Dec 13, 2018
AAPL Buy Dec 10, 2018
QCOM Sell Dec 10, 2018
AAPL Buy Dec 10, 2018
QCOM Sell Dec 10, 2018
IBM Sell Dec 10, 2018
GWW Sell Jan 8, 2018
GWW Sell Jan 8, 2018
— First Eagle global Fund Class 1 Sell Jan 2, 2018

Amounts are reported as STOCK Act range buckets, not exact dollar values. Trade dates are the date the politician executed the trade; filing dates are when the disclosure was filed. Sign up to filter by ticker, amount range, or filing window.

LoBiondo, Frank A. stock trade activity

FilingIQ has indexed 75 congressional stock trade disclosures for LoBiondo, Frank A.. The most recent disclosed transaction is dated Dec 14, 2018.

Across the full history, 16 purchases and 57 sales have been disclosed under the STOCK Act.

Top tickers traded by LoBiondo, Frank A.

Frequently asked

How many stock trades has LoBiondo, Frank A. disclosed?
FilingIQ tracks 75 Periodic Transaction Report disclosures for LoBiondo, Frank A., with the most recent dated Dec 14, 2018. Every entry sources back to the official House Office of the Clerk or Senate Office of Public Records.
Is LoBiondo, Frank A. a net buyer or net seller?
Across the disclosed trade history, 16 (21%) were purchases and 57 (76%) were sales. Compensation and exchanges are filtered out of these counts.
Where does FilingIQ's data on LoBiondo, Frank A. come from?
Every trade shown on this page is sourced from the STOCK Act disclosures filed with the House or Senate. FilingIQ normalizes ticker resolution, dates, and amount brackets across both chambers.

Methodology & sources

Disclosures parsed from official House Office of the Clerk and Senate Office of Public Records filings. Methodology documented on methodology. Compiled by Thomas Kraaibeek. Not investment advice; see disclaimer.